What did researchers report at the 2026 European Society of Cardiology Congress and in The New England Journal of Medicine about CRISPR Therapeutics’ one-time, liver-targeted CRISPR-Cas9 therapy CTX310—including how its lipid-nanoparticle delivery switches off ANGPTL3 to mimic a

Researchers reported that a single infusion of investigational CTX310 produced durable, large reductions in ANGPTL3, LDL cholesterol, and triglycerides in a small Phase 1a study. It is promising proof-of-concept—not evidence yet that it prevents cardiovascular events or can replace standard lipid-lowering treatment. 12

• CTX310 packages CRISPR-Cas9 in lipid nanoparticles designed to reach the liver and create a permanent loss-of-function edit in ANGPTL3. The rationale is to reproduce the lipid-lowering, cardioprotective phenotype observed in people with naturally occurring ANGPTL3 loss-of-function variants. 25

• The dose-escalation Phase 1a trial enrolled 15 adults with severe, treatment-refractory dyslipidemia—familial hypercholesterolemia, elevated triglycerides, or mixed dyslipidemia—despite maximally tolerated lipid treatment. 15

• At the 0.8-mg/kg dose, the one-year report gave mean reductions of approximately 53% in LDL cholesterol, 48% in triglycerides, and 79% in circulating ANGPTL3; the largest individual ANGPTL3 reduction was 89%. Thus, the figures in the question—52.5% and 47.8%—are consistent with more precise versions of the reported rounded LDL and triglyceride results. 67

• No serious adverse event was judged treatment-related. However, this should not be described as “no serious adverse events”: two participants had serious events, including a spinal-disc herniation and a sudden death 179 days after a 0.1-mg/kg dose, which investigators did not attribute to CTX310. 1

• A one-time treatment could, in principle, reduce dependence on lifelong daily drugs and thereby avoid adherence problems associated with chronic statin therapy. But cardiovascular-outcome benefit, durability beyond the current follow-up, off-target effects, and rare delayed harms remain unproven. 26

• CTX310 was being advanced into Phase 1b, prioritizing severe hypertriglyceridemia and refractory hypercholesterolemia; the company said it expected an update in the second half of 2026. The available sources support U.S. initiation and ex-U.S. work, but I could not independently verify the specific “up to 40 patients in the U.S. and Australia” enrollment claim from the primary materials retrieved. 47

• Long-term follow-up is important because edits are permanent. FDA guidance recommends long-term follow-up of gene-editing recipients for up to 15 years, based on product-specific risks and the possibility of delayed adverse effects, including unintended editing effects. 3